TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02696031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Study: NCT04030104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reader Study Imagio Ultrasound + Optoacoustic Imaging
Description: Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Mammography as available per standard of care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Mammography as available per standard of care
Study: NCT03598738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg oral tablet, once a day
Study: NCT02935634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03717519

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of platelet count at diagnosis
Description: Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
Study: NCT02018094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine
Description: Intra-operative skin preparation prior to incision to skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine
Description: Intra-operative skin preparation prior to incision to skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine
Description: Intra-operative skin preparation prior to incision to skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
Study: NCT01377259

Intervention type: OTHER
Intervention: tissue oxygen saturation, spinal anesthesia
Description: regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia

Intervention type: OTHER
Intervention: tissue oxygen saturation, spinal anesthesia
Description: regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
Study: NCT02806869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of ibuprofen (800 mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of ibuprofen (800 mg tablet)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulmocare, two 8.0 oz (236.6 mL) cans
Study: NCT01097343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 75 mg
Description: 75 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 150 mg
Description: clopidogrel 150 mg
Study: NCT03253913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
Study: NCT01321606

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Description: Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10\^10 organisms

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill (placebo)
Description: Placebo identical to the active product will be given
Study: NCT02053363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (Cyklokapron)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (Cyklokapron)
Study: NCT02200159

Intervention type: DRUG
Intervention: Sedation with dexmedetomidine
Study: NCT03731312

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study and no interventions will be administered.
Study: NCT02785380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery(LS)
Description: For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
Study: NCT02539212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: microwave ablation
Description: ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
Study: NCT05116839

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: the first 15 minutes with pressure support ventilation
Description: PSV pressure support ventilation:triggered by minute volume \< 3 Liter ,with no frequency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode
Description: continous positive air way pressure CPAP mode at 10 cm H2o .

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: i gel air way
Description: supraglottic air way device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i gel air way
Description: supraglottic air way device
Study: NCT04628715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSA biofeedback
Description: Biofeedback intervention based on breathing at resonance frequency

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSA biofeedback
Description: Biofeedback intervention based on breathing at resonance frequency

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RSA biofeedback
Description: Biofeedback intervention based on breathing at resonance frequency
Study: NCT03812978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone application
Description: Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
Study: NCT03630939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR-114
Description: ESR-114 Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR-114
Description: ESR-114 Topical Gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Gel
Study: NCT01622075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please
Description: SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte
Description: Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
Study: NCT03951207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuampin 10/5mg
Description: Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuampin 20/5mg
Description: Rosuampin 20/5mg qd for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine/Atorvastatin 5/20mg
Description: Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
Study: NCT03900637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate
Description: In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MammaPrint
Description: In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
Study: NCT03907098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: an anti-angiogenesis drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Physician's choice
Study: NCT01263730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
Study: NCT00761436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spheramine (BAY86-5280)
Description: Stereotactic Intrastriatal Implantation
Study: NCT02052375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous injection
Study: NCT02935634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Specified dose on specified days
Study: NCT02310802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE001 dose 1
Description: OBE001 dispersible tablets for single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE001 dose 2
Description: OBE001 dispersible tablets for single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE001 dose 3
Description: OBE001 dispersible tablets for single oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dispersible tablets for single oral administration
Study: NCT02730845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular dexmedetomidine
Description: Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous dexmedetomidine
Description: Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
Study: NCT01419275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon contrast agent
Study: NCT02018094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Alcoholic Chlorhexidine skin pre-op preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Alcoholic Chlorhexidine skin pre-op preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Alcoholic Chlorhexidine skin pre-op preparation
Study: NCT01419275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon contrast agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Arterial spin label sequence for the purpose of measuring collateral flow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Arterial spin label sequence for the purpose of measuring collateral flow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Arterial spin label sequence for the purpose of measuring collateral flow

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Arterial spin label sequence for the purpose of measuring collateral flow
Study: NCT02486510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours
Study: NCT02018094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
Study: NCT04688346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HemeRX epinephrine pellets
Description: Racemic Epinephrine Pellet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HemeRX epinephrine pellets
Description: Racemic Epinephrine Pellet
Study: NCT03524833

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: Twenty patients receive intraluminal Metronidazole eradication of H. pylori.

Intervention type: DRUG
Group type: OTHER
Intervention: Lansoprazole, Amoxicillin, Metronidazole
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
Study: NCT02074579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU-100
Description: 15g daily, orally as 5g three times daily for 4 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given 5g three times daily orally for 4 consecutive weeks
Study: NCT01542359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogic practice
Description: breathing, meditation, physical postures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise
Description: Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
Study: NCT02018094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
Study: NCT00597935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSLF
Description: sacrospinous ligament fixation (SSLF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSLF
Description: sacrospinous ligament fixation (SSLF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULS
Description: uterosacral vaginal vault ligament suspension (ULS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULS
Description: uterosacral vaginal vault ligament suspension (ULS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMT
Description: Pelvic muscle training and exercises (PMT)
Study: NCT04224493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Stage 2:~Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
Study: NCT00597935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMT
Description: Pelvic muscle training and exercises (PMT)
Study: NCT01163162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 2 mcg oral Paricalcitol once per day for 7 days
Study: NCT00563836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: 10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
Study: NCT03005977

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urodynamics
Description: UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.